[1] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[2] Younossi Z M, Koenig A B, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84.
[3] Loomba R, Lawitz E, Mantry P S, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial[J]. Hepatology, 2018, 67(2): 549-559.
[4] Tao L, Yang X, Ge C, et al. Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH[J]. Cell Metab, 2024, 36(10): 2190-2206.e5.
[5] Lee J, Vali Y, Boursier J, et al. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(9): e0238717.
[6] Pimentel C F, Jiang Z G, Otsubo T, et al. Poor inter-test reliability between CK18 kits as a biomarker of NASH[J]. Dig Dis Sci, 2016, 61(3): 905-912.
[7] Abdelhameed F, Kite C, Lagojda L, et al. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD[J]. Curr Obes Rep, 2024, 13(3): 510-531.
[8] Sanyal A J, Shankar S S, Yates K P, et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis[J]. Nat Med, 2023, 29(10): 2656-2664.
[9] Zhang X, Shen J, Man K, et al. CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis[J]. J Hepatol, 2014, 61(6): 1365-1375.
[10] Potoupni V, Georgiadou M, Chatzigriva E, et al. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: a systematic review and a meta-analysis[J]. J Gastroenterol Hepatol, 2021, 36(11): 3002-3014.
[11] Gastaldelli A, Sabatini S, Carli F, et al. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH[J]. Liver Int, 2021, 41(11): 2659-2670.
[12] Gallego-Durán R, Ampuero J, Maya-Miles D, et al. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression[J]. United European Gastroenterol J, 2024, 12(8): 1056-1068.
[13] Huang Y, Li J, Song S, et al. Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD[J]. Cell Rep Med,2026 Jan 20,7(1):102522.
[14] Gao F, He Q, Li G, et al. A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis[J]. Liver Int, 2022, 42(1): 80-91.
[15] Suhimoto K, Moriyasu F, Dioguardi Burgio M, et al. US markers and necroinflammation, steatosis, and fibrosis in metabolic dysfunction-associated steatotic liver disease: the iLEAD study[J]. Radiology, 2024, 312(2): e233377.
[16] Lee D H, Cho E J, Bae J S, et al. Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19(4): 797-805.e7.
[17] Jang J K, Lee E S, Seo J W, et al. Two-dimensional shear-wave elastography and US attenuation imaging for nonalcoholic steatohepatitis diagnosis: a cross-sectional, multicenter study[J]. Radiology, 2022, 305(1): 118-126.
[18] Pierce T T, Ozturk A, Sherlock S P, et al. Reproducibility and repeatability of US shear-wave and transient elastography in nonalcoholic fatty liver disease[J]. Radiology, 2024, 312(3): e233094.
[19] Pavlides M, Banerjee R, Tunnicliffe E M, et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity[J]. Liver Int, 2017, 37(7): 1065-1073.
[20] Alkhouri N, Beyer C, Shumbayawonda E, et al. Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH[J]. J Hepatol, 2025, 82(3): 438-445.
[21] Komiyama Y, Motosugi U, Maekawa S, et al. Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography[J]. Hepatol Res, 2023, 53(3): 208-218.
[22] Allen A M, Shan V H, Therneau T M, et al. The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery[J]. Hepatology, 2020, 71(2): 510-521.
[23] Wu X X, Zheng K I, Boursier J, et al. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study[J]. EClinicalMedicine, 2021, 41: 101145.
[24] Huang Q, Qadri S F, Bian H, et al. A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease[J]. J Hepatol, 2025, 82(5): 781-793.
[25] Funada K, Kusano Y, Gyotoku Y, et al. Novel multi-parametric diagnosis of non-alcoholic fatty liver disease using ultrasonography, body mass index, and Fib-4 index[J]. World J Gastroenterol, 2023, 29(23): 3703-3714.
[26] Lee Y S, Lee J E, Yi H S, et al. MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease[J]. Hepatol Int, 2022, 16(2): 316-324.
[27] Boursier J, Anty R, Vonghia L, et al. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH[J]. Aliment Pharmacol Ther, 2018, 47(10): 1387-1396.
[28] Chuah K H, Wan Yusoff W N I, Sthaneshwar P, et al. MACK-3 (combination of hoMa, AST and CK18): a promising novel biomarker for fibrotic non-alcoholic steatohepatitis[J]. Liver Int, 2019, 39(7): 1315-1324.
[29] Huang X, Zhu T, Li S, et al. Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery[J]. Hepatology, 2025 Nov 13.
[30] FDA. FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events[EB/OL].(2025-08-27). https://www.fda.gov/drugs/drug-safety-and-availability/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related
[31] Newsome P N, Sasso M, Deeks J J, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(4): 362-373.
[32] Mózes F E, Lee J A, Vali Y, et al. Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis[J]. Liver Int, 2024, 44(8): 1872-1885.
[33] Ravaioli F, Dajti E, Mantovani A, et al. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis[J]. Gut, 2023, 72(7): 1399-1409.
[34] Noureddin M, Truong E, Gornbein J A, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis[J]. J Hepatol, 2022, 76(4): 781-787.
[35] Feng G, Mózes F E, Ji D, et al. acFibroMASH Index for the diagnosis of Fibrotic MASH and prediction of liver-related events: an international multicenter study[J]. Clin Gastroenterol Hepatol, 2025, 23(5): 785-796.
[36] Fichez J, Mouillot T, Vonghia L, et al. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials[J]. JHEP Rep, 2025, 7(4): 101351.
[37] Loomba R, Amangurbanova M, Bettencourt R, et al. MASH resolution index: development and validation of a non-invasive score to detect histological resolution of MASH[J]. Gut, 2024, 73(8): 1343-1349.
[38] Loomba R, Daniel P C N, Amangurbanova M, et al. Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy[J]. Hepatology, 2026,83(4):907-914.
[39] Feng G, Boursier J, de Saint Loup M, et al. Fibrotic MASH resolutionVCTE index to diagnose fibrotic MASH resolution and predict LREs: a global multicenter study[J]. Med, Published online December 22, 2025. |
